Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer by Leffers, Ninke et al.
  
 University of Groningen
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of
advanced stage ovarian cancer
Leffers, Ninke; Gooden, Marloes J. M.; de Jong, Renske A.; Hoogeboom, Baukje-Nynke; ten






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Leffers, N., Gooden, M. J. M., de Jong, R. A., Hoogeboom, B-N., ten Hoor, K. A., Hollema, H., ... Nijman, H.
W. (2009). Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of
advanced stage ovarian cancer. Cancer Immunology Immunotherapy, 58(3), 449-459.
https://doi.org/10.1007/s00262-008-0583-5
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Cancer Immunol Immunother (2009) 58:449–459
DOI 10.1007/s00262-008-0583-5
ORIGINAL ARTICLE
Prognostic signiWcance of tumor-inWltrating T-lymphocytes 
in primary and metastatic lesions of advanced 
stage ovarian cancer
Ninke LeVers · Marloes J. M. Gooden · Renske A. de Jong · Baukje-Nynke Hoogeboom · 
Klaske A. ten Hoor · Harry Hollema · H. Marieke Boezen · Ate G. J. van der Zee · 
Toos Daemen · Hans W. Nijman 
Received: 11 June 2008 / Accepted: 21 August 2008 / Published online: 13 September 2008
©  The Author(s) 2008. This article is published with open access at Springerlink.com
Abstract
Purpose Ovarian cancer patients with intra-tumoral CD3+
T-lymphocytes in primary tumor tissue have a better prog-
nosis. This study aims to analyze the presence and relative
inXuence of three important T-lymphocyte subsets, tumor-
inWltrating CD8+ cytotoxic T-lymphocytes (CTL), CD45R0+
memory T-lymphocytes, and FoxP3+ regulatory T-lympho-
cytes (Treg), in primary tumor tissue and omental metasta-
ses of patients with ovarian cancer.
Experimental design The number of CD8+, CD45R0+,
and FoxP3+ T-lymphocytes was determined by immunohis-
tochemistry on a tissue micro array containing ovarian
tumor tissue and/or omental metastases obtained at primary
debulking surgery from 306 FIGO stage I–IV ovarian can-
cer patients. Immunohistochemistry data were correlated to
clinicopathological parameters and survival data.
Results High number of CD8+ CTL and a high CD8+/
FoxP3+ ratio in ovarian-derived tumor tissue were associ-
ated with increased disease-speciWc survival and proved to
be independent prognostic factors in multivariate analyses.
In advanced stage patients, the presence of CD8+ CTL,
CD45R0+ memory T-lymphocytes, FoxP3+ Treg or a high
CD8+/FoxP3+ ratio in ovarian-derived tumor tissue was
associated with an increased disease speciWc survival in
univariate analysis, as was the presence of CD45R0+
memory T-lymphocytes and FoxP3+ Treg in omental
metastases. Furthermore, in advanced stage patients CD8+
cytotoxic and FoxP3+ regulatory T-lymphocytes inWltrating
ovarian-derived tumor tissue were independent predictors
of increased prognosis.
Conclusions T-lymphocytes inWltrating primary and met-
astatic ovarian cancer sites are associated with improved
prognosis. These associations are especially distinct in
advanced stage patients, underlining the potential for
immunotherapy as a broadly applicable therapeutic
strategy.
Keywords Ovarian cancer · Memory T-lymphocytes · 
Omental metastasis
Introduction
Ovarian cancer is the most frequent cause of death from
gynecological malignancies, with an overall mortality of
60%. Due to its lack of speciWc symptoms, 70% of patients
present with advanced disease. Initial treatment consists of
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Even when initial treatment is successful, many patients
relapse. There is no curative secondary treatment in case of
residual disease after chemotherapy or relapse [13, 22].
Therefore, new therapeutic strategies are under investiga-
tion [1]. Immunotherapy is one of these strategies and has
yielded especially promising results in fundamental and
animal research. However, clinical applications have only
shown limited eYcacy. Further knowledge is necessary to
develop strategies to increase clinical eYcacy of immuno-
therapy.
Tumor-inWltrating lymphocytes (TIL) were found to cor-
relate with improved prognosis in several types of cancer
[8, 12, 14, 25, 29, 33]. The presence of TIL is considered a
reXection of the immune response to the tumor. However,
not all T-lymphocyte subsets contribute equally to this
observed positive eVect on prognosis. Invasion by cytotoxic
T-lymphocytes (CTL) has been found to be advantageous
in ovarian cancer [25] and several other types of cancer [15,
19, 20, 26]. The role of CD4+ T-lymphocytes is ambiguous.
Non-regulatory CD4+ helper T-lymphocytes, especially of
the Th1 subset, are considered to be beneWcial in cancer, in
general [32]. Regulatory CD4+ T-lymphocytes (Treg) have
a physiological function in preventing autoimmunity. They
may induce peripheral tolerance, and in doing so, suppress
immune responses. In cancer, Treg traYc to tumors as a
result of chemokines produced by tumor cells and microen-
vironmental macrophages [9]. There, they suppress eVector
T-lymphocytes by secreting transforming growth factor 
(TGF-) and interleukin 10 (IL-10) or by direct cell–cell
contact [9]. Treg have been found to unfavorably inXuence
prognosis in ovarian cancer [9, 30]. From a functional point
of view, the ratio between eVector T-lymphocytes and regu-
latory T-lymphocytes may be even more interesting, as was
demonstrated by Sato et al. [25] who showed that high
ratios of CTL/helper T-lymphocytes and CTL/Treg were of
prognostic signiWcance, whereas no signiWcant association
between the number of tumor inWltrating T-lymphocytes in
general or subsets (Treg/helper T-lymphocytes) and overall
survival were found in ovarian cancer. A less well studied
T-lymphocyte subset are memory T-lymphocytes, which
may arise after the initial immune response against an
antigen. In cancer, memory T-lymphocytes mediate long-
term immunity against tumors [21]. The presence of
intra-tumoral memory T-lymphocytes is associated with
increased survival in hepatocellular [6] and colorectal
cancer [12, 21]. To our knowledge, no studies have been
published investigating the presence of memory T-
lymphocytes in ovarian cancer. In summary, patients with
tumor-inWltrating T-lymphocytes mount an immune
response against their tumor, the success of which seems to
depend on the relative concentrations of diVerent T-cell
subtypes.
No reports have been published describing possible
diVerences in T-lymphocyte inWltration patterns between
primary tumor sites and metastases. The omentum is a fre-
quent site for metastases in ovarian cancer, due to the dis-
placement of tumor cells by the peritoneal Xuid stream. We
decided to study the presence of inWltrating T-lymphocytes
in omental metastases, which was greatly facilitated by the
fact that omentectomy is a routine part of cytoreductive sur-
gery. We compared the results with inWltrating T-lympho-
cytes in tissue taken from the primary ovarian tumor.
Aims of the present study were to determine the pres-
ence of CD8+ CTL, CD45R0+ memory T-lymphocytes, and
FoxP3+ Treg in primary tumor specimens and simultaneous
omental metastases of patients with ovarian cancer and to
determine their prognostic impact.
Methods
Patients
As of 1985, the Department of Gynecological Oncology at
the University Medical Center Groningen (UMCG) keeps a
computerized database of patients with malignant epithelial
ovarian cancer treated at this hospital at any time point,
during the course of their disease, prospectively collecting
information on clinicopathologic characteristics and fol-
low-up.
For this study, ovarian cancer patients were selected if
primary surgery was performed by a gynecological oncolo-
gist from the UMCG between May 1985 and June 2006 and
if paraYn-embedded ovarian and omental tumor tissue was
available.
Patients were staged according to FIGO classiWcation
[7]. Tumors were graded and classiWed according to WHO
criteria by a gynecological pathologist [27]. Adjuvant
chemotherapy consisted of diVerent platinum-based treat-
ment regimens. Response to chemotherapy was evaluated
according to WHO criteria [31]. After treatment, patients
were followed-up for at least 10 years with gradually
increasing intervals. Follow-up data were completed for all
patients until January 2007.
Institutional Review Board Approval
For the present study, all relevant data were retrieved from
our computerized database into a separate anonymous data-
base. In this separate password-protected database, patient
identity was protected by study-speciWc, unique patient
codes, which were only known to two dedicated data
managers, who also have daily responsibility for the larger
database. In case of uncertainties with respect to clinico-
pathological and follow-up data, the larger databases could123
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taining the protection of patients’ identity. According to
Dutch law no approval from our IRB was needed.
Tissue micro arrays
Tissue micro arrays (TMA) were constructed as described
in previous studies [16, 24]. In brief, paraYn-embedded tis-
sue blocks containing tumor in ovarian and omental tissue,
and corresponding hematoxylin & eosin (H&E) stained
slides were retrieved from the pathology archives. Repre-
sentative areas of tumor were marked on the H&E stained
slides. Next, using these H&E slides for reference, four
0.6 mm core biopsies were taken from each tumor speci-
men and arrayed on a recipient paraYn block using a tissue
microarrayer (Beecher instruments, Silver Spring, Mary-
land, USA). Adhesion of cores to the recipient block was
accomplished by placing the blocks in a 37°C oven for
15 min. For staining, 4 m sections were cut from each
TMA block. H&E staining was performed to verify the
presence of tumor in the arrayed samples.
Immunohistochemistry
TMA sections were stained with mouse monoclonal anti-
bodies recognizing CTL (anti-CD8; Dako cytomation,
Glostrup, Denmark), memory T-lymphocytes (anti-
CD45R0 clone OPD4; Labvision, Fremont, CA, USA) and
Treg (anti-FoxP3 m22509, Abcam, Cambridge, UK). In
brief, TMA sections were dewaxed in xylene and rehy-
drated using graded concentrations of ethanol to distilled
water. After antigen retrieval, endogenous peroxidase
activity was blocked by submersion of sections in a 0.3%
H2O2 solution for 30 min. Sections were incubated with
the primary antibody for 60 min at room temperature
(dilutions: anti-CD8 1:20; anti-CD45R0 1:50; anti-FoxP3
1:100). Sections incubated with anti-CD45R0 and anti-
FoxP3 were subsequently incubated with DAKO Envision+
for 30 min. For sections incubated with anti-CD8, RAMpo
(dilution 1:100) and GARpo (dilution 1:100) were used
as secondary and tertiary antibodies, respectively. The
antigen-antibody reactions were visualised with 3,3-
diaminobenzidine or NovaRED™ (Vector Laboratories,
Burlingame) for anti-FoxP3 staining. Sections were coun-
terstained with hematoxylin.
Scoring
All stainings were scored independently by two observers.
Observers had no prior knowledge of clinicopathological
information. For the anti-CD8 and anti-CD45R0 staining,
the number of cells with membrane staining within tumor
epithelium was counted for each core. For the anti-FoxP3
staining, the number of cells with nuclear staining within
tumor-islets in every core was counted. To obtain a high
concordance rate with whole tissue slides, we decided that
minimally two cores with a minimum of 20% tumor tissue
had to be present on the TMA for a sample to be entered
into analysis [24]. Subsequently, we calculated the number
of intra-tumoral cells per 0.283 mm2 of tumor (i.e., one
whole core consisting of 100% tumor tissue), to correct for
diVerences in the amount of tumor tissue and to standardize
the analysis. This calculation entailed dividing the total
number of intra-tumoral cells in cores containing ¸20% of
tumor by the total percentage of tumor tissue present in
these cores.
Statistics
The distribution of all TIL subtypes was positively skewed.
For further analysis, we therefore decided to categorize
patients using the bottom tertile (p33) as a cut-oV value
[25]. However, when the bottom tertile equaled zero, a sub-
division based on the presence or absence of these cells was
made for further analysis. Associations between clinico-
pathological characteristics and intra-tumoral T-lympho-
cytes were tested using the 2 test. DiVerences in numbers
of tumor-inWltrating T-lymphocytes between primary ovar-
ian tumor tissue and omental metastases were tested using
Wilcoxon Signed Ranks test. Disease-speciWc survival
(DSS) was deWned as date of surgery until death due to
ovarian cancer or date of last follow-up. DSS was estimated
using Kaplan Meier and Log Rank test, it was used to
assess for survival diVerences between groups. Cox propor-
tional hazards models were used for multivariate analyses
and were stratiWed for type of chemotherapy. Only vari-
ables that were signiWcantly associated with DSS in the uni-
variate analyses were entered into multivariate analyses.
Survival analyses were performed in the total population as
well as in a subgroup which included all advanced stage
patients. For all tests, p values <0.05 were considered sig-
niWcant. All p values were tested two-sided. All statistical
analyses were performed using SPSS 14.0 software pack-
age for windows (SPSS Inc., Chicago, IL, USA).
Results
Study population
From a total of 306 ovarian cancer patients, suYcient par-
aYn-embedded ovarian and/or omental tissue containing
epithelial ovarian carcinoma was available for construction
of the TMA (Fig. 1a). Tumor-containing ovarian tissue was
available from 270 patients. From 111 (41.1%) of these
patients tumor-containing omental tissue was also available.123
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an addition of 36 patients. Clinicopathological characteris-
tics of patients are summarized in Table 1. Forty-two
patients did not receive chemotherapy, 28 of them were
diagnosed with FIGO stage I disease. The remaining 14
patients were either not Wt or unwilling to receive chemo-
therapy. Of the patients treated with chemotherapy 89.5%
received a platinum-based regimen. The median survival
for all patients was 37.4 months with an estimated 5-year
disease-speciWc survival of 41%.
Tumor-inWltrating T-lymphocytes
Intra-tumoral CD8+, CD45R0+, and FoxP3+ T-cells were
present in 91.2, 47.0, and 53.2% of primary ovarian tissue,
respectively (representative examples in Fig. 1b–d), while
intra-tumoral CD8+, CD45R0+, and FoxP3+ T-cells were
present in 96.2, 49.3 and 73.1% of omental metastases,
respectively.
In both ovarian and omental derived tumor tissue, the
number of tumor-inWltrating T-lymphocytes was positively
associated with each other for all subtypes (Tables 2, 3).
Although the median number of tumor-inWltrating
T-lymphocytes was higher for omental than ovarian
tissue, no diVerences in intra-tumoral T-lymphocytes
were observed between ovarian and omental tumor tis-
sue within patients for whom both samples were avail-
able (data not shown).
Association of tumor-inWltrating lymphocytes 
with clinicopathological parameters
Tables 2 and 3 show the relationship of clinicopathological
parameters to the presence of intra-tumoral TIL in ovary
and omentum derived tumor tissue, respectively. In ovarian
tissue, the presence of FoxP3+ cells was positively associ-
ated with advanced stage disease (p = 0.031). Furthermore,
patients with poorly diVerentiated tumors were more likely
to have intra-tumoral FoxP3+ cells compared to patients
with well-diVerentiated tumors (p = 0.011). Also, patients
younger than 59 years at time of diagnosis were more likely
to have a low CD8+/CD45R0+ ratio than older patients
(data not shown: 48.5 vs. 34.3%, p = 0.036).
In omental metastases, high CD8+ T-cell numbers were
associated with <2 cm residual disease after primary debul-
king surgery (p = 0.035). A similar association was found
for FoxP3+ cells, which were more often present in patients
with residual disease of <2 cm (p = 0.028).
Survival analysis
In agreement with expectations, well-known prognostic
factors such as age ¸59 years, advanced stage disease,
poorly diVerentiated tumors, serous tumors and ¸2 cm
residual disease after primary debulking surgery were asso-
ciated with a shorter disease-speciWc survival (data not
shown). Furthermore, univariate analysis of disease-speciWc
Fig. 1 Immunohistochemical 
staining of tumor-inWltrating 
T-lymphocytes in ovarian cancer 
tissue. a Flow diagram showing 
the type of tissue analyzed and 
the percentage of patients lost 
from analysis. Patients were 
excluded from analysis when 
less than two tissue cores with at 
least 20% tumor were present for 
evaluation. b Intra-tumoral 
CD8+ T-lymphocytes, c 
CD45R0+ T-lymphocytes, 
d FoxP3+ T-lymphocytes 
at 400£ magniWcation123
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with high numbers of intra-tumoral CD8+ cytotoxic T-lym-
phocytes in ovarian-derived tumor tissue, which subsides
after 10 years of follow-up (p = 0.042, Fig. 2a). Disease-
speciWc survival was not inXuenced by the presence of
CD45R0+ memory T-lymphocytes, FoxP3+ regulatory T-
lymphocytes in ovarian tissue. However, median DSS of
patients with a high CD8+/FoxP3+ ratio in ovarian-derived
tumor tissue was twice as high as for patients with a low
CD8+/FoxP3+ ratio (50.0 vs. 23.0 months, p = 0.014,
Fig. 2b). For the CD8+/CD45R0+ ratio a trend was
observed towards a longer median DSS in patients with a
high ratio (51.7 vs. 30.9 months, p = 0.056).
We subsequently repeated univariate survival analyses
using a subgroup consisting of patients with advanced stage
disease. Interestingly, in this subgroup a prolonged median
DSS was observed for all T-lymphocyte subsets studied
in ovarian-derived tumor tissue, except for the CD8+/
CD45R0+ ratio (30.5 vs. 15.6 months, p = 0.076), i.e.,
CD45R0+ lymphocytes (n = 155, 37.3 vs. 16.4 months,
p = 0.009, Fig. 2c), CD8+ lymphocytes (n = 150, 30.3 vs.
12.2 months, p = 0.012, Fig. 2d), FoxP3+ lymphocytes
(n = 149, 30.3 vs. 14.0 months, p = 0.008, Fig. 2e) and a
high CD8+/FoxP3+ ratio (n = 146, 30.3 vs. 14.6 months;
p = 0.016, Fig. 2f). Similarly, univariate analysis of dis-
ease-speciWc survival diVerences based on the presence of
Table 1 Clinicopathological 
characteristics and survival data Total (n = 306) Primary ovarian 
cancer (n = 270)
Metastatic omental-
ovarian cancer (n = 147)
Age (years)
Mean (SD) 57.2 (13.5) 56.8 (13.8) 59.6 (12.2)
DSS (months)
Median (95% CI) 37.4 (25.6–49.2) 45.4 (31.1–59.8) 20.4 (14.3–27.3)
FIGO Stage
Stage I 67 (21.9%) 67 (24.8%)
Stage II 24 (7.8%) 25 (9.3%)
Stage III 171 (55.9%) 145 (53.7%) 116 (78.9%)
Stage IV 42 (13.7%) 32 (11.9%) 30 (20.4%)
Missing 2 (0.7%) 1 (0.4%) 1 (0.7%)
Tumor type 
Serous 171 (55.9%) 147 (54.4%) 105 (71.4%)
Mucinous 36 (11.8%) 35 (13.0%) 6 (4.1%)
Endometroid 41 (13.4%) 38 (14.1%) 13 (8.8%)
Clear cell 21 (6.9%) 18 (6.7%) 7 (4.8%)
Adenocarcinoma 13 (4.2%) 10 (3.7%) 5 (3.4%)
Mixed tumours 15 (4.9%) 14 (5.2%) 5 (3.4%)
Other 9 (2.9%) 8 (3.0%) 6 (4.1%)
Tumor grade
Grade I 52 (17.0%) 51 (18.9%) 6 (4.1%)
Grade II 80 (26.1%) 76 (28.1%) 28 (19.0%)
Grade III 135 (44.1%) 113 (41.9%) 91 (61.9%)
UndiVerentiated 14 (4.6%) 11 (4.1%) 9 (6.1%)
Missing 25 (8.2%) 19 (7.0%) 13 (8.8%)
Residual disease
<2 cm 162 (52.9%) 157 (58.1%) 47 (32.0%)
¸2 cm 123 (40.2%) 92 (34.1%) 94 (63.9%)
Missing 21 (6.9%) 21 (7.8%) 6 (4.1%)
Chemotherapy 
No chemotherapy 42 (13.7%) 40 (14.8%) 12 (8.2%)
Platinum-containing 117 (38.2%) 104 (38.5%) 48 (32.7%)
Platinum and taxane containing 113 (36.9%) 96 (35.6%) 69 (46.9%)
Other regimen 27 (8.8%) 24 (8.9%) 16 (10.9%)
Unknown 7 (2.3%) 6 (2.2%) 2 (1.4%)
DSS disease-speciWc survival, 
FIGO International Federation 
of Gynaecology and Obstetrics123
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only in patients with advanced stage disease, showed an
increased survival in patients with intra-tumoral FoxP3+
Treg (25.6 vs. 14.7 months, p < 0.008, Fig. 2g) and
CD45R0+ memory T-lymphocytes (24.3 vs. 15.6 months,
p = 0.031, Fig. 2h).
Multivariate analysis was performed stratiWed for type of
chemotherapy. For all patients as well as the advanced
stage subgroup, the above-mentioned well-known prognos-
tic factors and tumor-inWltrating T-lymphocytes were
entered into the Cox proportional hazards model (Table 4).
In the analysis using all patients, CD8+ lymphocytes and
CD8+/FoxP3+ ratio were independent prognostic factors for
DSS (HR 0.36, 95% CI 0.22–0.59, p < 0.001; respectively,
HR 0.53, 95% CI 0.32–0.85, p = 0.009), next to commonly
acknowledged risk factors as stage of disease, diVerentia-
tion grade and amount of residual tumor after primary
debulking surgery. When analyzing only patients with
advanced stage disease, a high number of CD8+ cytotoxic
lymphocytes in ovarian-derived tumor tissue was demon-
strated to be an independent prognostic factor for longer
DSS (HR 0.35, 95% CI 0.21–0.60, p < 0.001), as was the
presence of FoxP3+ Treg (HR 0.55, 95% CI 0.34–0.88,
p = 0.013). Additionally, multivariate analysis was per-
formed using the absolute number of tumor-inWltrating T-
lymphocytes in stead of the dichotomized variables (data
not shown). Unlike CD8+ lymphocytes, FoxP3+ lympho-
cytes inWltrating tumor epithelium remained an indepen-
dent factor for longer DSS (HR 0.937, 95% CI 0.88–1.00,
p = 0.035).
Table 2 Relationship of tumor-inWltrating lymphocytes in ovarian tissue to clinicopathological parameters and each other (N, %)
FIGO International Federation of Gynaecology and Obstetrics
a p values were calculated using Pearson 2 test
Bold signiWes p < 0.05















<59 43 (38.7) 68 (61.3) 0.101 61 (55.0) 50 (45.0%) 0.571 48 (44.9) 59 (55.1) 0.575
¸59 33 (28.4) 83 (71.6) 62 (51.2) 59 (48.8) 54 (48.6) 57 (51.4)
FIGO stage
Stage I/II 25 (33.3) 50 (66.7) 0.947 45 (59.2) 31 (40.8%) 0.173 39 (57.4) 29 (42.6) 0.031
Stage III/IV 51 (33.8) 100 (66.2) 77 (49.7) 78 (50.3) 62 (41.6) 87 (58.4)
Tumor type
Serous 37 (30.3) 85 (69.7) 0.278 68 (52.7) 61 (47.3) 0.917 51 (42.1) 70 (57.9) 0.125
Non-serous 39 (37.1) 66 (62.9) 55 (53.4) 48 (46.6) 51 (52.6) 46 (47.4)
DiVerentiation grade
Grade I/II 39 (37.5) 65 (62.5) 0.208 56 (54.9) 46 (45.1) 0.513 55 (57.3) 41 (42.7) 0.011
Grade III and undiV. 32 (29.4) 77 (70.6) 57 (50.4) 56 (49.6) 43 (39.4) 66 (60.6)
Residual disease
<2 cm 45 (36.0) 80 (64.0) 0.692 64 (48.9) 67 (51.1) 0.109 58 (50.4) 57 (49.6) 0.577
¸2 cm 28 (33.3) 56 (66.7) 51 (60.0) 34 (40.0) 39 (46.4) 45 (53.6)
CD8+ T-lymphocyte
Lowest tertile 55 (76.4) 17 (23.6) <0.001 53 (75.7) 17 (24.3) <0.001
All others 58 (42.0) 80 (58.0) 47 (32.9) 96 (67.1)
CD45R0+ T-lymphocyte
Absent 66 (70.2) 41 (37.6) <0.001
Present 28 (29.8) 68 (62.4)
CD8+/FoxP3+ ratio
Bottom tertile 41 (63.1) 24 (26.9) 0.038
All others 64 (47.4) 71 (52.6)
CD8+/CD45R0+ ratio
Bottom tertile 50 (64.1) 28 (35.9) <0.001
All others 43 (35.5) 78 (64.5)123
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The observation of an improved survival of patients with
intra-tumoral T-lymphocytes suggests an important role for
the immune system in the natural course of ovarian cancer
[33]. In the present study, we analyzed the relative contri-
bution of diVerent tumor-inWltrating T-lymphocyte sub-
types to this observed improvement of survival. To our
knowledge, this is the Wrst study to examine the prognostic
inXuence of diVerent tumor-inWltrating T-lymphocytes in
primary as well as metastatic lesions. We show improved
disease-speciWc survival in advanced stage ovarian cancer
patients with CD45R0+ memory T-lymphocytes and/or
FoxP3+ regulatory T-lymphocytes inWltrating ovarian-
derived tumor tissue and/or omental metastases. In addi-
tion, we also conWrm important previous observations by
others of improved survival in patients with either a high
number of tumor-inWltrating CD8+ cytotoxic T-lympho-
cytes or a high CD8+/FoxP3+ ratio [25].
Intra-tumoral CD45R0+ T-lymphocytes, present in
approximately 50% of patients, were associated with
increased DSS when present in ovarian-derived tumor tis-
sue and omental metastases. Although its expression is not
restricted to memory T-lymphocytes, CD45R0 is com-
monly used as a marker for memory T-lymphocytes [4, 12,
21]. Upon antigenic stimulation, naïve T-lymphocytes
diVerentiate into eVector T-lymphocytes, but also memory
T-lymphocytes can be formed. The latter assure a strong
and speedy immune response on subsequent exposures to
the same antigen. The presence of tissue-inWltrating mem-
ory T-lymphocytes thus implies prior exposure to an anti-
gen encountered in the tissue environment, which in case of
tumor-inWltrating memory T-lymphocytes may very well
reXect an anti-tumor response of the immune system. The
presence of a survival beneWt for patients with high levels
of inWltrating memory T-lymphocytes was previously
described in colorectal cancer [12, 21]. The cell numbers
seen in these studies were remarkably higher than those
Table 3 Relationship of tumor-inWltrating lymphocytes in omental tissue to clinicopathological parameters and each other (N, %)
FIGO International Federation of Gynaecology and Obstetrics
a p values were calculated using Pearson 2 test
Bold signiWes p < 0.05















<59 28 (38.4) 45 (61.6) 0.173 38 (53.5) 33 (46.5) 0.495 28 (39.4) 43 (60.6) 0.653
¸59 16 (27.1) 43 (72.9) 30 (47.6) 33 (52.4) 21 (35.6) 38 (64.4)
Tumor type
Serous 32 (33.3) 64 (66.7) 1,000 52 (54.7) 43 (45.3) 0.149 38 (40.4) 56 (59.6) 0.299
Non-serous 12 (33.3) 24 (66.7) 16 (41.0) 23 (59.0) 11 (30.6) 25 (69.4)
DiVerentiation grade
Grade I/II 12 (41.4) 17 (58.6) 0.244 15 (51.7) 14 (48.3) 0.871 12 (42.9) 16 (57.1) 0.356
Grade III and undiV. 28 (29.8) 66 (70.2) 47 (50.0) 47 (50.0) 31 (33.3) 62 (66.7)
Residual disease
<2 cm 7 (18.9) 30 (81.1) 0.035 18 (46.2) 21 (53.8) 0.488 8 (22.2) 28 (77.8) 0.028
¸2 cm 34 (38.2) 55 (61.8) 47 (52.8) 42 (47.2) 38 (43.2) 50 (56.8)
CD8+ T-lymphocyte
Lowest tertile 35 (79.5) 9 (20.5) <0.001 29 (59.2) 14 (17.5) <0.001
All others 29 (34.5) 55 (65.5) 20 (40.8) 66 (82.5)
CD45R0+ T- lymphocyte
Absent 36 (73.5) 27 (34.6) <0.001
Present 13 (26.5) 51 (65.4)
CD8+/FoxP3+ ratio
Bottom tertile 28 (66.7) 14 (33.3) 0.007
All others 35 (41.2) 50 (58.8)
CD8+/CD45R0+ ratio
Bottom tertile 34 (59.6) 23 (40.4) <0.001
All others 22 (27.5) 58 (72.5)123
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may be explained in several ways. Firstly, no distinction
was made between tumor- and peri-tumoral stroma inWltrating
cells in these studies, whereas we only report tumor-
inWltrating memory T-lymphocytes. Secondly, when repeat-
ing our analysis on the total cell count/core we still did not
observe levels similar to that in colorectal cancer, although
results for the survival analysis were comparable to the
analysis with tumor-inWltrating memory T-lymphocytes
only (data not shown). A more likely explanation is that the
higher number of inWltrating lymphocytes in colon tissue
could be considered inherent to its daily exposure to foreign
products and pathogens, an observation which does not
hold for ovarian tissue.
Our data show that patients with intra-tumoral CTL inWl-
trations and/or a high CTL/Treg ratio in tumor-containing
ovarian tissue consistently have the longest disease-speciWc
survival, conWrming the results previously described in a
smaller population of ovarian cancer patients [25]. How-
ever, unlike previous studies in ovarian cancer addressing
the prognostic inXuence of Treg [9, 25], we found tumor-
inWltrating Treg to be an independent positive factor for
Fig. 2 Disease-speciWc survival (in months) of ovarian cancer pa-
tients based on tumor-inWltrating lymphocytes. Cumulative survival
time was estimated by the Kaplan–Meier method. Log Rank test was
used to evaluate survival diVerences between groups. High numbers of
CD8+ T-lymphocytes (a) and a high CD8+/Foxp3+ ratio (b) in ovarian-
derived tumor tissue were associated with improved survival in FIGO
stage I–IV disease. In advanced stage patients, a survival beneWt was
observed for patients with CD45R0+ T-lymphocytes (c) CD8+ T-lym-
phocytes (d), FoxP3+ T-lymphocytes (e) a high CD8+/FoxP3+ ratio (f)
in ovarian-derived tumor tissue. Furthermore, FoxP3+ (g) and
CD45R0+ T-lymphocytes (h) in omental metastases were associated
with improved disease-speciWc survival123
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disease. One possible explanation is the fact that although
FoxP3 is currently the best marker available for immuno-
histochemical staining of Treg on paraYn embedded tissue,
it is not exclusively expressed in regulatory cells. Recently,
it was shown that activated CD4+CD25¡ eVector T cells
transiently express FoxP3, without having regulatory activ-
ity [2, 23]. Possibly, the positive prognostic eVect of the
presence of FoxP3+ cells in our samples can be attributed to
the staining of not only suppressive, but also activated
T-lymphocytes expressing FoxP3. Similar observations of
positive eVects of Treg however, have been previously
reported in studies on immune cell malignancies and head
and neck squamous cell carcinoma (HNSCC), some of
which further phenotyped the FoxP3+ cells. A high number
of Treg is associated to longer survival in follicular
lymphoma and classic Hodgkin’s lymphoma [3, 18]. In
HNSCC where higher numbers of circulating Treg were
present in patients without evidence of disease after pri-
mary treatment compared to patients with active disease,
locoregional Treg were associated with better locoregional
control [5, 28]. Furthermore, the possible protective role for
Treg against cancer was also illustrated in murine models
of colorectal cancer, which show that adoptive transfer of
CD4+CD25+ regulatory cells results in regression of adeno-
mas [10, 11]. Although we Wnd that the presence of Treg is
associated with an increase in disease-speciWc survival, we
also Wnd that (1) the absolute number of Treg present does
not seem to alter this positive prognostic eVect, (2) the pres-
ence of Treg is strongly associated with high numbers of
CTL, and (3) a high CTL/Treg ratio is associated with a
longer disease-speciWc survival. It thus seems plausible that
it is not merely the presence of Treg, but rather the inWltra-
tion of tumor by T-lymphocytes in general which is respon-
sible for the observed survival advantage, as was previously
reported by Zhang et al. [33]. In this point of view, inWltra-
tion of tumor epithelium, or any other inXammatory site, by
lymphocytes is naturally accompanied by regulatory T-
cells and the eVectiveness of immune responses depends on
the proportion of the diVerent lymphocyte subtypes present
instead of on the presence of a particular subtype.
Unlike previous studies of TIL in ovarian cancer, we
have also studied the prognostic inXuence of TIL in omen-
tal metastases of ovarian cancer patients. Although TIL in
Table 4 Multivariate Cox regression analysis on disease-speciWc survival
Analyses were performed stratiWed for type of chemotherapy. FIGO International Federation of Gynecology and Obstetrics, HR hazard ratio,
CI conWdence interval, OV ovarian-derived tumor tissue, OM omental metastasis
Bold signiWes p < 0.05
HR 95% CI p value HR 95% CI p value HR 95% CI p value
All stages
Age ¸59 years 0.96 0.60–1.55 0.876 0.98 0.61–1.59 0.938
FIGO Stage III/IV 3.31 1.34–8.13 0.009 3.59 1.73–9.37 0.009
Grade III/undiVerentiated 1.97 1.19–3.27 0.008 1.64 0.98–2.74 0.059
Non-serous tumor 0.67 0.41–1.12 0.125 0.63 0.38–1.05 0.078
Residual tumor 3.38 2.27–6.44 <0.001 3.01 1.82–4.96 <0.001
CD8+ T-lymphocytes high (OV) 0.36 0.22–0.59 <0.001
CD8+/FoxP3+ ratio high (OV) 0.53 0.32–0.85 0.009
Advanced stage only
Age ¸ 59 years 0.82 0.50–1.36 0.444 1.02 0.63–1.64 0.945 0.99 0.60–1.64 0.979
Grade III/undiVerentiated 1.75 1.02–2.99 0.041 1.82 1.07–3.09 0.026 1.69 0.96–2.97 0.067
Non-serous tumor 0.76 0.44–1.30 0.309 0.77 0.44–1.33 0.346 0.72 0.42–1.23 0.229
Residual tumor 3.58 2.08–6.17 <0.001 2.41 1.50–3.88 <0.001 2.56 1.54–4.25 <0.001
CD8+ T-lymphocytes high (OV) 0.35 0.21–0.60 <0.001
CD45R0+ T-lymphocytes present (OV) 0.72 0.46–1.14 0.166
FoxP3+ T-lymphocytes present (OV) 0.55 0.34–0.88 0.013
Age ¸59 years 1.00 0.61–1.65 1.000 0.76 0.43–1.33 0.888 0.76 0.44–1.33 0.335
Grade III/undiVerentiated 1.42 0.83–2.44 0.205 1.04 0.57–1.89 0.910 1.29 0.70–2.37 0.417
Non-serous tumor 0.76 0.44–1.30 0.318 0.60 0.34–1.06 0.078 0.66 0.37–1.20 0.177
Residual tumor 2.50 1.51–4.15 <0.001 2.63 1.41–4.90 0.002 2.74 1.46–5.15 0.002
CD8+/FoxP3+ ratio high (OV) 0.68 0.42–1.08 0.099
CD45R0+ T-lymphocytes present (OM) 0.69 0.43–1.08 0.106
FoxP3+ T-lymphocytes high (OM) 0.64 0.39–1.06 0.082123
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ease-speciWc survival, we did show an increased survival in
univariate analysis for advanced stage patients with mem-
ory T-lymphocytes and Treg inWltrating omental metasta-
ses. Interestingly, median numbers of TIL were higher in
omental metastases than in ovarian-derived tumor tissue
and the percentage of patients with Treg in omental metas-
tases was substantially higher than for ovarian-derived
tumor tissue. The omentum may be considered a secondary
lymphoid tissue as it contains large aggregates of macro-
phages and lymphocytes, the so-called milky spots. These
milky spots contain mostly macrophages (68%), but T-lym-
phocytes are also present (10%) [17]. The high percentage
of patients with Treg observed in omental metastases and
the higher median cell counts as compared to ovarian-
derived tumor tissue may be a reXection of the lymphoid
function of the omentum.
In summary, we show that memory T-lymphocytes inWl-
trating ovarian-derived tumor tissue and omental metasta-
ses are associated with increased disease-speciWc survival
in patients with advanced stage disease. Unexpectedly, the
presence of regulatory T-lymphocytes in ovarian-derived
tumor tissue is also an independent factor for increased dis-
ease-speciWc survival. However, the fact that a high CTL/
Treg ratio independently predicts increased survival as
well, suggests that it is not so much the presence of Treg as
the presence of TIL in general that is responsible for the
observed survival eVect. Our results support the notion that
diVerent T-lymphocyte subsets play a unique and important
role in the natural course of ovarian cancer.
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